Adhering to current clinical guidance supports evidence-based assessment, informs decision-making, and helps reduce complications in patients living with autoinflammatory diseases. Ongoing review of recommendations and guidance enables clinicians to improve evaluation and management, which supports better patient outcomes.
Today's rundown features clinical guidance on autoinflammatory diseases that was published within the past few years. The following clinical guidance is presented in order of publication.
Autoinflammatory Disease Guidance
- Management of Behçet’s Syndrome
- European League Against Rheumatism (EULAR)
- March 2026
- Assessment of the Disease Activity in Adult-Onset Still’s Disease
- European League Against Rheumatism (EULAR)
- December 2025
- Diagnosis and Management of VEXAS
- American College of Rheumatology (ACR)
- August 2025
- Hidradenitis Suppurativa/Acne Inversa Part 2: Treatment
- European Academy of Dermatology and Venereology (EADV)
- December 2024
- Managing People with Behçets
- British Association of Dermatologists (BAD), British Society for Rheumatology (BSR)
- September 2024
- Diagnosis and Management of Still’s Disease, Comprising Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease
- European League Against Rheumatism (EULAR)
- September 2024
- Management of the IL-1-mediated Autoinflammatory Diseases,CAPS (FCAS, MWS and NOMID/CINCA), TRAPS, MKD and DIRA
- European League Against Rheumatism (EULAR)
- May 2022
- Management of the Autoinflammatory Type-I Interferonopathies
- European League Against Rheumatism (EULAR)
- February 2022
Check out other rheumatology-related content and sign up for alerts to stay informed on the latest published guidelines and insights.
